Alkermes (ALKS) director sells 2,000 shares under Rule 10b5-1 plan
Filing Impact
Filing Sentiment
Form Type
4
Rhea-AI Filing Summary
Alkermes plc director Christopher I. Wright reported an open-market sale of 2,000 Ordinary Shares at a price of $45.10 per share. After this transaction, he directly holds 25,680 Ordinary Shares.
The sale was executed under a pre-arranged Rule 10b5-1 trading plan adopted by Wright on March 11, 2026, indicating the trade was scheduled in advance rather than timed discretionarily.
Positive
- None.
Negative
- None.
Insider Trade Summary 10b5-1
Net Seller: 2,000 shares ($90,200)
Net Sell
1 txn
Insider
Wright Christopher I
Role
null
Sold
2,000 shs ($90K)
| Type | Security | Shares | Price | Value |
|---|---|---|---|---|
| Sale | Ordinary Shares | 2,000 | $45.10 | $90K |
Holdings After Transaction:
Ordinary Shares — 25,680 shares (Direct, null)
Footnotes (1)
- [object Object]
Key Figures
Shares sold: 2,000 shares
Sale price: $45.10 per share
Shares held after sale: 25,680 shares
+1 more
4 metrics
Shares sold
2,000 shares
Open-market sale of Alkermes Ordinary Shares
Sale price
$45.10 per share
Price for 2,000 Ordinary Shares sold
Shares held after sale
25,680 shares
Direct ownership following the transaction
Net shares sold
2,000 shares
Net-sell direction from transaction summary
Key Terms
Rule 10b5-1 trading plan, open-market sale, Ordinary Shares
3 terms
Rule 10b5-1 trading plan financial
"This sale was effected pursuant to a Rule 10b5-1 trading plan adopted..."
A Rule 10b5-1 trading plan is a pre-arranged schedule that allows company insiders to buy or sell stock at specific times, even if they have inside information. It helps prevent accusations of unfair trading by making these transactions look planned and transparent, rather than sneaky or illegal.
open-market sale financial
"transaction_action: open-market sale"
An open-market sale is when a shareholder sells existing shares directly on a public exchange to any willing buyer, rather than through a private deal. Think of it like putting goods on a busy market stall where price is set by supply and demand; for investors it matters because such sales increase available supply, can put short-term downward pressure on the stock price, and signal changes in liquidity or investor confidence.
FAQ
What insider transaction did Alkermes (ALKS) disclose for Christopher Wright?
Alkermes reported that director Christopher I. Wright sold 2,000 Ordinary Shares in an open-market transaction at $45.10 per share. Following the sale, he directly owns 25,680 Ordinary Shares of Alkermes, as reflected in the Form 4 filing.
Was the Alkermes (ALKS) insider sale made under a Rule 10b5-1 plan?
Yes. The Form 4 footnote states the 2,000-share sale was effected under a Rule 10b5-1 trading plan adopted by Christopher I. Wright on March 11, 2026. Such plans pre-schedule trades, reducing the role of discretionary timing.
What type of security did Christopher Wright trade in Alkermes (ALKS)?
Christopher I. Wright traded Alkermes Ordinary Shares in this Form 4 transaction. The filing identifies the security as “Ordinary Shares” and classifies the event as a non-derivative, open-market sale of 2,000 shares at $45.10 each.